Distinct Clinical Phenotypes Associated with JAK2V617F Reflect Differential STAT1 Signaling  by Chen, Edwin et al.
Cancer Cell
ArticleDistinct Clinical Phenotypes
Associated with JAK2V617F
Reflect Differential STAT1 Signaling
Edwin Chen,1 Philip A. Beer,1,2 Anna L. Godfrey,1,2 Christina A. Ortmann,1,2 Juan Li,1 Ana P. Costa-Pereira,3
Catherine E. Ingle,4 Emmanouil T. Dermitzakis,4 Peter J. Campbell,4 and Anthony R. Green1,2,*
1Cambridge Institute for Medical Research and Department of Haematology, University of Cambridge, Hills Road, Cambridge, CB2 0XY, UK
2Department of Haematology, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0XY, UK
3Imperial College London, Department of Surgery and Cancer, Hammersmith Hospital, London W12 0NN, UK
4The Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK
*Correspondence: arg1000@cam.ac.uk
DOI 10.1016/j.ccr.2010.10.013SUMMARYThe JAK2V617F mutation is associated with distinct myeloproliferative neoplasms, including polycythemia
vera (PV) and essential thrombocythemia (ET), but it remains unclear how it generates disparate disorders.
By comparing clonally-derived mutant and wild-type cells from individual patients, we demonstrate that
the transcriptional consequences of JAK2V617F are subtle, and that JAK2V617F-heterozygous erythroid
cells from ET and PV patients exhibit differential interferon signaling and STAT1 phosphorylation. Increased
STAT1 activity in normal CD34-positive progenitors produces an ET-like phenotype, whereas downregula-
tion of STAT1 activity in JAK2V617F-heterozygous ET progenitors produces a PV-like phenotype. Our results
illustrate the power of clonal analysis, indicate that the consequences of JAK2V617F reflect a balance
between STAT5 and STAT1 activation and are relevant for other neoplasms associated with signaling
pathway mutations.INTRODUCTION
The myeloproliferative neoplasms (MPNs) are hematological
malignancies characterized by a chronic clinical course and
a risk of thrombosis and transformation to acute leukemia. These
disorders are an attractive model for understanding the earliest
stages of cancer development because many patients present
at an early stage with an incidental abnormal blood count, the
landscape of causative somatic mutations underpinning the
disorders is increasingly well understood and tumor cells can
be grown and differentiated in vitro from single progenitor cells.
The two most common MPNs are polycythemia vera (PV), in
which patients present with a raised red cell mass sometimes
associated with increased platelet and white cell counts, and
essential thrombocythemia (ET), which is defined by an elevated
platelet count but normal red cell mass.Significance
Our results reveal a central role for STAT1 activation in the path
phenotypic consequences of JAK2V617F reflect a balance bet
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relevance: (1) the transcriptional consequences of JAK2V617F
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524 Cancer Cell 18, 524–535, November 16, 2010 ª2010 Elsevier IncTheMPNs result from transformation of a multipotent hemato-
poietic progenitor (Adamson et al., 1976; Delhommeau et al.,
2007; Fialkow et al., 1981; Jamieson et al., 2006). In 95% of
patients with PV and 60% of those with ET, an identical somat-
ically acquired mutation is found in the tyrosine kinase, JAK2
(Baxter et al., 2005; James et al., 2005; Kralovics et al., 2005a;
Levine et al., 2005). This V617F mutation results in dysregulated
kinase activity of JAK2 and produces ligand-independent activa-
tion of receptor signaling in cytokine-dependent cell lines. It has
been suggested that expression of a homodimeric type I
cytokine receptor provides a scaffold necessary for optimal
signaling by mutant JAK2 (Lu et al., 2008; Lu et al., 2005) and
several signaling cascades are activated by mutant JAK2,
including the STAT5, MAPK, and PI3K pathways (James et al.,
2005; Kralovics et al., 2005a; Laubach et al., 2009; Levine
et al., 2005; Oku et al., 2010). Of these, the STAT5 pathwayogenesis of JAK2V617F-positive MPNs and indicate that the
ween hematopoietic effects of STAT1 and STAT5 activation.
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Figure 1. Strategy for Analysis of Paired Normal and JAK2V617F Samples from MPN Patients
BFU-E colonies were grown from 20 ET and 16 PV patients in methylcellulose media supplemented with 0.01 U/ml erythropoietin, individually plucked and gen-
otyped for JAK2V617Fmutation burden. Up to 20 wild-type and V617F-heterozygous colonies were pooled and subjected to further analysis. See also Figure S1.
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Differential STAT1 Activity in JAK2-Mutant MPNhas been shown to be necessary and sufficient for at least some
aspects of the MPN phenotype in vitro and in vivo (Funakoshi-
Tago et al., 2010; Garcon et al., 2006; Grebien et al., 2008; Ilaria
et al., 1999). Drosophila studies have also revealed a noncanon-
ical pathway bywhich JAK2 regulates chromatin (Shi et al., 2006;
Shi et al., 2008) and a direct nuclear function for JAK2 as
a histone H3 kinase has recently been reported (Dawson et al.,
2009). The JAK2V617F mutation is sufficient to cause an MPN
phenotype in mouse models (Akada et al., 2010; Lacout et al.,
2006; Li et al., 2010; Marty et al., 2010; Mullally et al., 2010; Tiedt
et al., 2008; Wernig et al., 2006; Xing et al., 2008; Zaleskas et al.,
2006) and, taken together, existing data demonstrate that muta-
tion of JAK2 plays a central and early role in MPN pathogenesis.
One fundamental, unresolved question is how the samemuta-
tion in JAK2 can give rise to phenotypically distinct disorders
such as ET and PV. Homozygosity for the mutation is common
in JAK2V617F-positive PV but rare in JAK2V617F-positive ET
(Scott et al., 2006), thus raising the possibility that increased
signaling through JAK2V617F may be responsible for the PV
phenotype. However, attempts to identify different signaling
consequences in ET and PV have not yielded consistent results
using western blotting (Heller et al., 2006), immunohistochem-
istry (Grimwade et al., 2009; Teofili et al., 2007), or expression
profiling (Berkofsky-Fessler et al., 2010; Goerttler et al., 2005;
Kralovics et al., 2005b; Laubach et al., 2009; Pellagatti et al.,
2003; Puigdecanet et al., 2008; Slezak et al., 2009; Tenedini
et al., 2004). This is likely to reflect several issues that complicate
interindividual comparisons including constitutional variation in
transcript levels among normal individuals (Stranger et al.,
2005; Stranger et al., 2007), the widely varying proportions of
wild-type and mutant clones present in samples obtained from
different patients (Dupont et al., 2007; Scott et al., 2006) and
treatment differences across patient cohorts. Such difficulties
undoubtedly confound similar laboratory studies of other
cancers as well, but are generally difficult to identify or quantify
and have therefore often not been formally evaluated.
To circumvent these issues, we took advantage of the trac-
table clinical and laboratory features of MPNs to devise
a strategy based on analysis of clonally-derived cells genotypedCanfor JAK2 mutation status. This approach allows comparison of
pure populations of phenotypically equivalent mutant and wild-
type cells grown from the same patient under identical condi-
tions, and has allowed us to address the mechanisms respon-
sible for the different phenotypic consequences of the JAK2
mutation in ET and PV.
RESULTS
JAK2V617F-Associated Transcriptome Changes
Are Less Marked than Those Due to Interindividual
Differences and Can Be Identified by Clonal Analysis
In patients with MPNs, erythroid colonies containing thousands
of cells can be grown by in vitro culture in semisolid media.
Each colony represents the in situ expansion of a single erythroid
progenitor cell and so reflects the genetic landscape of the
initiating cell. Because JAK2 mutant and wild-type progenitor
cells coexist in the peripheral blood of patients with ET and PV,
colonies from both genotypes can be grown in the same exper-
iment, individually picked and typed for presence or absence of
the V617Fmutation, pooled by genotype, and studied for pheno-
typic differences (Figure 1). This strategy enables direct compar-
ison of mutant and wild-type cells within a patient, thereby
controlling for differences in age, sex, treatment, germline
genetic background, experimental factors, and other confound-
ing variables. Laboratory assays that can be applied to pheno-
type such colonies are flexible and wide-ranging: in this study,
we present results of transcriptional profiling, conventional and
intracellular flow cytometry, western immunoblotting, as well
as immunohistochemistry.
A total of 5302 BFU-E colonies from 36 MPN patients (20 ET
and 16 PV; Table S1 available online) were grown, collected,
genotyped, and pooled based on presence or absence of the
JAK2V617F mutation. For each patient a pool of JAK2V617F-
heterozygous erythroid colonies was compared to a pool of
JAK2V617F-negative colonies using gene expression microar-
rays. We chose to study erythroid cells because it is the
presence or absence of a raised red cell mass that is the key
distinction between PV and ET. The high erythropoietincer Cell 18, 524–535, November 16, 2010 ª2010 Elsevier Inc. 525
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Differential STAT1 Activity in JAK2-Mutant MPNconcentrations normally used in erythroid colony assays may
mask transcriptional consequences of the JAK2 mutation, and
so colonies were grown in 0.01 U/ml erythropoietin, a concentra-
tion shown to maximize the difference in expression of a known
JAK/STAT target (PIM1) between mutant and wild-type colonies
(Figure S1A). Comparison of colonies with and without the
JAK2V617F mutation revealed no overt differences in colony
morphology or size (Figure S1B), and no detectable differences
in the degree of erythroblast differentiation (assessed by GPA
and CD71 expression and morphological analysis of cytospins)
(Figures S1C and S1D), demonstrating that colonies from the
two genotypes represented comparable stages of erythroid
development. Gene set enrichment analysis did not show any
enrichment of erythroid differentiation genes among genes upre-
gulated in mutant colonies compared to wild-type colonies
(p = 0.2) or among mutant PV colonies compared to mutant ET
colonies (p = 0.19).
Unsupervised clustering analysis of expression profiles from
the two classes of colony demonstrated that JAK2 mutant
colonies were more closely related to wild-type colonies from
the same patient than to mutant colonies from other patients
(Figure 2A). There was no clustering based on other parameters,
such as diagnosis, therapy, age, or gender. To ensure that this
pattern of clustering did not reflect simultaneous processing of
paired samples from a given patient, repeat blood samples
were drawn from four individuals and subjected to the entire
process ab initio. The resulting expression profiles still revealed
close clustering between samples derived from the same
patient, with samples of the same genotype from the same
patient clustering closer yet (Figure S2A). Moreover, the ratio
of gene expression between the V617F-heterozygous and
wild-type colonies for all genes revealed strong concordance
in experiments carried out independently (Figure S2B). These
results demonstrate first that variability attributable to interassay
differences was minimal, and second that the transcriptional
consequences of the JAK2 mutation are less marked than
normal interindividual variation.
To identify V617F-associated genes common to both PV and
ET, expression profiles derived from all 36 patients were exam-
ined to identify genes consistently dysregulated in V617F-hetero-
zygous colonies relative to autologous wild-type colonies. After
adjustment for age, gender, and therapy, and controlling the false
discovery rate (FDR) at 10% for multiple hypothesis testing,
expression levels of 201 genes were increased in V617F-hetero-
zygous cells and those of 22 genes were reduced (minimum fold
change, 1.3; p values% 0.0034; Figures S2C and S2D). Gene set
enrichment analysis (GSEA) was applied to a preranked gene list
ordered according to the significance with which they were
differentially expressed in mutant and wild-type colonies.
Components of the erythropoietin signaling pathway (net enrich-
ment score [NES] = 1.51; q = 0.02) and previously reported
targets of STAT5A signaling (NES = 1.40; q = 0.09) (Olthof
et al., 2008) were enriched among genes upregulated in mutant
colonies (Figure 2B). Array results from individual patients for
known JAK/STAT targets (PIM1 and CISH) showed upregulation
associated with presence of the JAK2 mutation in most (but not
all) patients and were confirmed by quantitative RT-PCR in at
least five PV and five ET patients (Figure 2C). Consistent with
these data, nuclear pSTAT5 was increased in JAK2V617F-526 Cancer Cell 18, 524–535, November 16, 2010 ª2010 Elsevier Incheterozygous but not wild-type erythroblasts from both PV and
ET patients (Figure 2D).
Together these data demonstrate that the effect of the V617F
mutation on the transcriptome is surprisingly subtle, and less
than the influence of interindividual variation. However, compar-
ison of clonally-derived mutant and wild-type cells from each
patient permits identification of mutation-associated expression
changes.
JAK2V617F-Heterozygous Erythroid Cells from ET
and PV Patients Exhibit Differential Interferon
Signaling and STAT1 Phosphorylation
We next investigated whether gene expression changes asso-
ciated with JAK2V617F-heterozygous erythroid colonies were
the same in patients with ET and PV. After adjustment for
potential confounders including age, gender, and therapy,
a linear mixed effects (LME) modeling algorithm was applied
to the data set to identify genes for which a significant interac-
tion existed between JAK2 mutation status and MPN subtype
(i.e., ET or PV). This type of analysis has the advantage of allow-
ing for correction of interindividual variability without the need
to explicitly model it (Li et al., 2004). Controlling the FDR at
10%, a total of 171 genes exhibited significant interaction, all
of which fell into one of four basic patterns of gene behavior
(Figure S3A): (1) genes upregulated in JAK2 mutant
erythroblasts specifically in ET but not PV (n = 83); (2) genes
downregulated in JAK2 mutant erythroblasts specifically in ET
but not PV (n = 21); (3) genes upregulated in JAK2mutant eryth-
roblasts specifically in PV but not ET (n = 40); and (4) genes
downregulated in JAK2 mutant erythroblasts specifically in PV
but not ET (n = 24) (p % 0.0028). A hierarchical clustering
showing these combined 171 genes and their ability to subdi-
vide the PV patients from the ET patients is shown in a heat
map (Figure 3A). Linear discriminant analysis and leave-one-
out cross-validation using the 12 most statistically significant
genes resulted in correct classification of 33/36 (92%) of the
patients; an identical classification rate was determined using
the Stanford PAMR software. Taken together, these data
demonstrate cell-intrinsic differences in JAK2V617F-heterozy-
gous erythroblasts from PV and ET.
To investigate pathways associated with JAK2V617F expres-
sion in ET and PV, GSEA was applied to the entire gene list
ranked in order from those ‘‘most significantly up-regulated in
association with JAK2V617F in ET, compared to PV’’ to those
‘‘most significantly up-regulated in association with JAK2V617F
in PV, compared to ET.’’ At a FDR cut-off of 20%, 23 gene sets
were enriched for genes upregulated in ET, of which seven
were related to interferon signaling whereas 0/25 gene sets en-
riched for genes upregulated in PV were interferon related (Fig-
ure 3B, Table S2). We then looked for interferon-regulated genes
among the genes significantly upregulated by JAK2V617F in an
ET-selective or in a PV-selective manner. Interferon regulated
genes were defined by their presence in the Interferome data-
base (Samarajiwa et al., 2009), a group of manually curated
gene sets comprising known IFNa and IFNg target genes. Of
the 83 genes upregulated in an ET-selective manner, 26 were
IFN targets (8 IFNg targets, 2 IFNa targets, and 16 targets of
both). By contrast, only one of 40 genes upregulated in a PV-
selective manner were targets of either interferon (Table S4)..
Figure 2. JAK2V617F-Associated Transcriptional Changes Are Less than Those Due to Interindividual Differences and Include Activation of
STAT5 Signaling
(A) Dendrogram constructed from unsupervised hierarchical clustering of all 72 data sets (paired wild-type and V617F-heterozygous data sets from 20 ET and
16 PV patients) using Pearson correlation. Data sets from PV patients (listed PV.1–PV.16) are depicted as light red for expression profiles from wild-type eryth-
roblasts and dark red for expression profiles from V617F-heterozygous erythroblasts, with each patient connected by a line to their two-paired expression
profiles. Data sets for ET patients (ET.1–ET.20) are similarly depicted as light blue for expression profiles fromwild-type erythroblasts and dark blue for expression
profiles from V617F-heterozygous erythroblasts.
(B) Gene set enrichment analysis for genes significantly associated with V617F mutation across all MPN patients. Enrichment was seen for gene sets comprised
of components of the erythropoietin pathway and for STAT5A targets.
(C) qPCR validation of PIM1 andCISH upregulation in V617F-heterozygous erythroblasts. Fold increase represents the ratio of gene expression in V617F-hetero-
zygous compared to wild-type erythroblasts, with each data point representing an individual ET (blue) or PV (red) patient.
(D) Immunocytochemical staining of cytospins of wild-type and V617F-heterozygous BFU-E pools from PV and ET patients (left panel). Histograms show signif-
icantly higher numbers of cells positive for pY694-STAT5 in V617F-heterozygous colonies compared to wild-type colonies in both PV and ET (right panel). Scale
bars represent 5 mm. Results represent the mean ± SD for three PV and three ET patients. See also Figure S2.
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Differential STAT1 Activity in JAK2-Mutant MPNReal-time qPCR confirmed increased transcript levels of five
known IFNg target genes (IFI44L, GBP2, IRF1, HLA-F, IFITM3)
in V617F-heterozygous relative to autologous wild-type erythro-
blasts in 10 ET patients but not in 9 PV patients (Figure 3C).
These results demonstrate that JAK2V617F is associated with
enhanced IFN signaling, predominantly involving the IFNgCanpathway, in erythroblasts from patients with ET but not in those
from patients with PV.
Wild-type JAK2 binds the IFNRG1 component of the IFNg het-
erodimeric receptor (Ihle, 1994; Parganas et al., 1998; Silvennoi-
nen et al., 1993), and our results suggest that JAK2V617F
enhances activity of this pathway in JAK2 mutant erythroblastscer Cell 18, 524–535, November 16, 2010 ª2010 Elsevier Inc. 527
Figure 3. . Activation of Interferon Signaling and STAT1 Phosphorylation in JAK2V617F-Heterozygous Erythroblasts from Patients with ET
but Not Those with PV
(A) Hierarchical clustering of V617F-associated expression profiles of all 36 patients according to the 171 genes that showed significant interaction between the
V617F mutation and each disease class (i.e., PV or ET). Each gene is expressed as a ratio of expression in V617F-heterozygous to autologous wild-type sample.
Bars at the top of the graph display disease phenotype for each patient (blue: ET; red: PV).
(B) GSEA demonstrates that targets of interferon signaling are enriched among genes upregulated by JAK2V617F in ET but not PV.
(C) Real-time quantitative RT-PCR analysis of five IFNg target genes (IFI44L,GBP2, IRF1,HLA-F, IFITM3) in V617F-heterozygous and wild-type colonies from ET
patients (n = 10) and PV patients (n = 9). Fold increase represents the ratio of gene expression in V617F-heterozygous relative to autologous wild-type erythro-
blasts, with each data point representing an individual ET (blue) or PV (red) patient. Closed points represent patients used in the gene expression profiling; open
points represent a patient from an independently derived validation cohort.
(D) Intracellular flow cytometry shows elevated expression of pY701-STAT1 in V617F-heterozygous BFU-E colonies relative to autologous wild-type colonies
from ET patients (n = 6), and not in PV patients (n = 5).
(E) pY701-STAT1 staining of cytospins of wild-type and V617F-heterozygous BFU-E pools from PV and ET patients (left panel). Histogram depicts increase in
percentage of cells positive for pSTAT1 in V617F-heterozygous colonies from ET patients only compared to PV (right panel). Scale bars represent 5 mm. Results
represent the mean ± SD for three PV and three ET patients. See also Figure S3.
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Differential STAT1 Activity in JAK2-Mutant MPNfrom ET patients. Indeed, relative to expression of wild-type
JAK2, expression of JAK2V617F in g2A cells (which lack endog-
enous JAK2) resulted in increased STAT1 phosphorylation on the
tyrosine-701 residue (pSTAT1) in response to IFNg (Figure S3B).
Similar results were obtained using 293T cells (Figure S3C).
These data demonstrate that, analogous to its well-documented
effects in conferring cytokine hypersensitivity on type I homodi-
meric cytokine receptors (Lu et al., 2008; Lu et al., 2005),
JAK2V617F also enhances signaling from IFNg receptors.
To investigate the mechanisms responsible for the striking
lack of interferon signaling in JAK2V617F-heterozygous erythro-
blasts from PV patients, we focused on STAT1 because it is
essential for IFNg receptor signaling (Gough et al., 2010). Levels
of pSTAT1 were measured in mutant and wild-type erythroblasts
from ET and PV patients using intracellular flow cytometry. Rela-
tive to autologous erythroblasts, elevated expression of pSTAT1
was seen in JAK2V617F-heterozygous erythroblasts from all six
ET patients tested but not in any of five PV patients (Figure 3D).
Consistent with these results, pSTAT1was detected by immuno-
fluorescence in the nucleus of JAK2 mutant erythroblasts from
ET but not PV patients (Figure 3E). Immunoblotting revealed no
differences in total STAT1 levels between mutant and wild-type
erythroblasts in either disease (Figure S3D).
These data demonstrate that JAK2V617F-heterozygous PV
erythroblasts lack detectable pSTAT1 and therefore provide
a mechanism for the differential activation of IFN signaling path-
ways in ET and PV.Increased STAT1 Activity Produces an ET-Like
Phenotype with Enhanced Megakaryocytic
Differentiation and Restrained Erythroid Differentiation
The results described above raised the possibility that differences
in the level of STAT1 activity may contribute to the distinct biolog-
ical features of ET and PV. ET is characterized by increasedmega-
karyopoiesis whereas the dominant feature of PV is enhanced
erythropoiesis. We therefore assessed the effect of altering
STAT1 activity on megakaryocytic and erythroid differentiation.
Lentiviral constructs were used to express wild-type or consti-
tutively active STAT1 (STAT1C) (Liddle et al., 2006) in the hema-
topoietic progenitor cell line K562, which was then induced to
undergomegakaryocytic or erythroid differentiation by exposure
to phorbol 12-myristate 13-acetate (PMA) or hemin respectively.
Transduction efficiencies for all constructs were >95% as deter-
mined by GFP positivity by FACS, and expression levels of exog-
enous STAT1 and STAT1C were equivalent but pSTAT1 levels
were only increased in cells expressing STAT1C (Figure 4A).
Low concentrations of PMA (insufficient to generate detectable
megakaryocytic differentiation of unmodified K562 cells)
induced substantial megakaryocytic differentiation of K562 cells
expressing STAT1C but not those expressing STAT1. K562 cells
expressing STAT1C upregulated the megakaryocytic markers
CD41 (Figure 4B), CD61 (Figure S4A) and GPIX (Figure 4C) and
also developed increased DNA ploidy (Figure 4D and Fig-
ure S4B). Exposure to hemin induced erythroid differentiation
as indicated by increased levels of g-globin transcripts and he-
moglobinization. However, the increases in g-globin transcripts
and hemoglobin levels were both inhibited in K562 cells express-
ing STAT1C (Figures 4E and 4G). These results demonstrate thatCanincreased STAT1 activity in K562 cells results in enhanced
megakaryocytic and repressed erythroid differentiation.
To confirm our results in primary hematopoietic progenitors,
purified CD34+ cord blood cells were infected with lentiviruses
expressing STAT1 or STAT1C and then grown in conditions
promoting either megakaryocytic or erythroid differentiation. At
day 3 postinfection, pSTAT1 was readily detected in cells ex-
pressing STAT1C but not in those expressing STAT1 (Figure 5A).
No differences in growth kinetics were detected in cells express-
ing either STAT1 isoformwhen cultured in either megakaryocytic
or erythroid conditions (Figure 5B). However, expression of
STAT1C increased the proportion of cells expressing the mega-
karyocytic markers CD41 (Figure 5C and Figure S5A), CD61 (Fig-
ure 5D and Figure S5B) and GPIX (Figure 5E), and also increased
the proportion of polyploid cells (Figure 5F and Figure S5C).
Moreover, expression of STAT1C resulted in a reduced propor-
tion of GPA+CD71+ erythroid cells (Figure 5G and Figure S5D)
and reduced levels of g-globin transcripts (Figure 5H). These
results accord with our K562 data and demonstrate that
increased STAT1 activity in primary hematopoietic progenitors
is sufficient to produce an ET-like phenotype with enhanced
megakaryocytic and reduced erythroid differentiation.
Downregulation of STAT1 Activity in JAK2V617F+
Progenitors from ET Patients Results in a PV-Like
Phenotype with Increased Erythroid and Reduced
Megakaryocytic Differentiation
To test the hypothesis that increased STAT1 activity constrains
erythropoiesis in patients with ET, a dominant negative form of
STAT1 (STAT1DN) was expressed in CD34+ hematopoietic stem
and progenitor cells derived from patients diagnosed with ET.
Toperformtheseexperimentsataclonal level,CD34+progenitors
were isolated fromtwoETpatients, infectedwitha lentiviruscontain-
inganemptyvector (VA)orexpressingacDNAencodingadominant
negative form of STAT1 (STAT1DN) in which the Tyr701 residue
was mutated to a phenylalanine (Walter et al., 1997). Infected cells
were subsequently sorted at one cell per well into media capable
of supporting both erythroid and megakaryocytic differentiation.
After 7 days in culture each clone was genotyped to identify
JAK2V617F mutant clones, which were subsequently expanded
in fresh media for an additional 7–14 days (Figure 6A). Within
3 weeks, three distinct categories of GFP+ JAK2V617F+ clones
were evident: GPA-expressing erythroid clones, CD41-expressing
megakaryocytic clones, and mixed erythromegakaryocytic clones
comprised of cells expressing GPA or CD41 (Figure 6B). In both
ET patients examined, the percentage of GFP+ erythroid clones
derived from cells infected with the STAT1DN lentivirus was
increased and that of the megakaryocytic clones was decreased
compared to cells infected with the empty vector (p < 0.05,
Fisher-Freeman-Halton test) (Figure6C). These resultsdemonstrate
that STAT1 activity is necessary to repress erythropoiesis in
JAK2V617F-heterozygous ET progenitors, and that reducing
STAT1 activity results in a switch to a PV-like phenotype with
increased erythroid and reduced megakaryocytic differentiation.
DISCUSSION
In this study, we address the apparent paradox that an identical
JAK2 mutation is associated with different clinical phenotypes.cer Cell 18, 524–535, November 16, 2010 ª2010 Elsevier Inc. 529
Figure 4. STAT1 Activation Enhances Megakaryocytic Differentiation and Inhibits Erythroid Differentiation in K562 Cells
(A) Western immunoblot shows increased pY701-STAT1 expression in K562 cells transduced with a constitutively active form of STAT1 (STAT1C), compared to
cultures transduced with an empty vector (VA) or wild-type STAT1 cDNA (STAT1WT).
(B) Representative FACSprofiles showing that PMA treatment results in increased numbers of CD41-expressing cells in the STAT1C-infected. Also note concom-
itant increase in cell size as assessed by forward scatter (FSC), consistent with amegakaryocytic-like phenotype. Results are representative of three independent
experiments.
(C) Real-time quantitative RT-PCR of PMA-treated K562 cells shows increased expression of GpIX transcripts in STAT1C-infected K562 cultures relative to VA
and STAT1WT-infected control cultures. Error bars represent standard deviation for three independent experiments.
(D) PMA treatment results in increased numbers of polyploid (>4n) cells in STAT1C-infected K562 cultures. Error bars represent standard deviation for three inde-
pendent experiments.
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Figure 5. STAT1 Activation Enhances
Megakaryocytic Differentiation and Inhibits
Erythroid Differentiation in Normal Human
Progenitors
(A) Intracellular flow cytometry to detect pSTAT1
in cord blood CD34+ cells after transduction
with lentiviruses expressing wild-type STAT1
(STAT1WT) or constitutively active STAT1C
(STAT1C). Presence of pY701-STAT1 was
detected in GFP+ subpopulation of STAT1C-trans-
duced cultures only.
(B) STAT1WT- and STAT1C-infected cells were
cultured in megakaryocytic differentiation condi-
tions (blue) or erythroid differentiation conditions
(red) (refer to Supplemental Experimental Proce-
dures). Total numbers of GFP+ cells during
12 days of culture under both differentiation condi-
tions are shown. Error bars represent standard
deviation for three independent cultures.
(C–F) Expression of STAT1C in cord blood-derived
CD34+ cells grown in conditions supporting
megakaryocyte differentiation result in increased
numbers of GFP+CD41+ cells (C), increased
numbersofGFP+CD61+cells (D), increasedexpres-
sion ofGpIX transcripts (E), and increased numbers
of polyploid (>4n) cells (F). Error bars represent
standard deviation for three independent cultures.
The data are representative of two independent
experiments.
(G–H) Expression of STAT1C in CD34+ cells grown
in conditions supporting erythroid differentiation
resulted in decreased numbers of GFP+GPA+
CD71+ cells (G), and decreased expression of
g-globin (H). Results represent mean ± SD for
three independent cultures. The data are repre-
sentative of two independent experiments. See
also Figure S5.
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Differential STAT1 Activity in JAK2-Mutant MPNUsing a strategy based on analysis of clonally derived and geno-
typically defined cell populations, we have circumvented the
problems associated with interindividual comparison of expres-
sion profiles. Our results illuminate the pathogenesis of the
MPNs and are also of broad relevance for cancer biology.
We report the surprising finding that, in the vast majority of PV
and ET patients, the expression profiles of JAK2V617F-positive
erythroid cells are more closely related to wild-type cells from(E) Real-time quantitative RT-PCR demonstrating lower levels of g-globin transcripts in STAT1C-infected K
control cultures after erythroid differentiation with hemin. Results represent mean ± SD for three independe
(F) o-Dianisidine staining showing decreased numbers of hemoglobin-positive cells in STAT1C expressing K56
mean ± SD for three independent cultures.
(G) Increased hemoglobin levels in STAT1C-expressing cells differentiated with hemin. Results represent the m
Figure S4.
Cancer Cell 18, 524–535, Nthe same individual than to mutant cells
from other patients. This observation
demonstrates that normal interindividual
variation in gene expression is greater
than the transcriptional consequences
of the JAK2 mutation, a finding with
relevance for many somatic genetic
lesions associated with cancer. Indeed,
it is increasingly recognized that quantita-tive differences in transcript levels are under genetic control
in both man (Stranger et al., 2005; Stranger et al., 2007) and
mouse (Breitling et al., 2008; Gerrits et al., 2009). Our results,
therefore, emphasize the power of comparing clonally-derived,
phenotypically equivalent cell populations from the same indi-
vidual, together with the importance of using physiological
levels of cytokines that do not swamp the signaling pathways
of interest.562 cultures relative to VA and STAT1WT-infected
nt experiments.
2 cells differentiated with hemin. Results represent
ean ± SD for three independent cultures. See also
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Figure 6. Downregulation of STAT1 Activity
in JAK2V617F-Heterozygous Progenitors
from ET Patients Results in a PV-Like
Phenotype with Increased Erythroid and
Reduced Megakaryocytic Differentiation
(A) Strategy for assessing erythroid/megakaryo-
cytic differentiation potential of CD34+ cells from
ET patients after expression of an empty vector
(VA) or a dominant negative STAT1 (DN).
(B) Typical FACS profiles illustrating the three
clone types generated: megakaryocytic, erythro-
cytic, and mixed.
(C) Histogram showing the relative proportions of
the three different types of GFP+ V617F+ clones
derived from cells infected with virus expressing
empty vector (VA) or the dominant negative
STAT1 (DN). Increased percentages of GFP+
erythroid clones and decreased percentages of
GFP+ megakaryocytic clones were derived from
cells infected with the DN lentivirus compared to
cells infected with the VA. Testing for statistical
significance was carried out using a Fisher-
Freeman-Halton test.
Cancer Cell
Differential STAT1 Activity in JAK2-Mutant MPNOur results also have implications for the strategy of individu-
alized cancer therapy, an approach based on the concept of
identifying genetic lesions in each tumor and using this informa-
tion to select targeted therapies. Mutant JAK2 activates multiple
receptor-associated pathways and we show that some of these,
such as STAT5 and STAT1, can have competing consequences.
Our results also demonstrate that patients can carry an identical
JAK2 mutation but harbor striking differences in the degree to
which the mutation activates the STAT1 pathway. The conse-
quences of inhibiting a particular activated kinase may therefore
be different for individual tumors and difficult to predict without
a detailed knowledge of the signaling environment within a given
tumor. Moreover, because some pathways downstream of an
activated kinase may, like STAT1 activation, restrain disease
evolution, therapeutic kinase inhibition could potentially result
in paradoxical tumor-enhancing effects.
The mechanism whereby a single JAK2 mutation can give
rise to distinct diseases has been a major lacuna in our under-Figure
JAK2V
In ET, J
STAT5
pSTAT
cytic d
JAK2V6
allowin
also red
532 Cancer Cell 18, 524–535, November 16, 2010 ª2010 Elsevier Inc.standing of MPN pathogenesis, and dis-
tinguishing JAK2V617F-positive ET from
PV represents a diagnostic challenge
when patients have borderline hemo-
globin levels. Patients with JAK2V617F-positive ET exhibit an increased erythroid drive but lack overt
erythrocytosis (Campbell et al., 2005), indicating the existence
of additional mechanisms that either constrain erythropoiesis in
JAK2 mutation-positive ET or enhance it in PV. We believe the
data presented here demonstrate that STAT1 is activated in
association with JAK2V617F in ET but not PV and that pSTAT1
levels provide a molecular marker that distinguishes these
disorders. Importantly, we demonstrate that inhibition of STAT1
signaling in ET progenitors resulted in enhanced erythropoiesis
and reduced megakaryopoiesis. Together, our results indicate
that the clinical phenotype developed by a given individual
reflects the opposing effects of STAT5 and STAT1 signaling.
In ET, the intact pSTAT1 response to JAK2V617F constrains
erythroid and promotes megakaryocytic differentiation—the
reduced pSTAT1 response in PV removes the ‘‘brake’’ on eryth-
ropoiesis, thus allowing the development of an overt erythrocyto-
sis, and also reduces megakaryopoiesis (Figure 7). This model is
consistent with previous studies of the effects of STAT5 and7. Model for the Different Effects of
617F in ET and PV
AK2V617F induces simultaneous activation of both
and STAT1 signaling pathways. Activation of
1 constrains erythroid and promotes megakaryo-
ifferentiation. In PV, reduced pSTAT1 response to
17F removes the ‘‘brake’’ on erythropoiesis, thus
g the development of an overt erythrocytosis, and
uces megakaryopoiesis.
Cancer Cell
Differential STAT1 Activity in JAK2-Mutant MPNSTAT1 on hematopoietic differentiation (Huang et al., 2007;
Olthof et al., 2008; Socolovsky et al., 1999).
Homozygosity for the JAK2mutation is common in PV but rare
in ET (Scott et al., 2006), and has been suggested as a potential
mechanism for increased erythropoiesis in PV (Dupont et al.,
2007) Our results show that reduced pSTAT1 levels precede
homozygosity and enhance erythropoiesis, but do not exclude
a subsequent role for JAK2V617F homozygosity. Once the
pSTAT1 pathway is repressed, homozygosity of JAK2V617F
would be predicted to enhance erythroid differentiation by
increasing pSTAT5 signaling. By contrast, in the presence of
intact STAT1 signaling, JAK2V617F homozygosity may fail to
confer any growth or selective advantage (or even result in
a disadvantage). We are collecting JAK2V617F-homozygous
colonies to investigate the transcriptional consequences of
homozygosity.
The process responsible for loss of STAT1 phosphorylation in
PV remains unclear. Our data do not distinguish between consti-
tutional or acquired mechanisms. However, the pSTAT1
response to IFNg is normal in T cells from patients with PV
(data not shown), indicating that there is no constitutional block
to STAT1 activation. Moreover, the fact that some patients with
high-risk ET develop overt PV transformation (Harrison et al.,
2005) argues for an acquired genetic modifier in at least a subset
of patients, a concept consistent with the observation that 10%
of JAK2V617F knock-in mice also develop PV transformation
(Li et al., 2010).
Our results also have implications for interferon therapy, HSC
behavior, and clonal evolution in the MPNs. JAK2mutant erythro-
blasts from PV patients have markedly reduced pSTAT1 levels
(relative to ET patients), and yet both categories of patients
respond to therapy with IFNa. This suggests that such responses
may reflect non cell-intrinsic mechanisms, that reduced STAT1
phosphorylation in PV can be overcome by pharmacological
doses of IFNa, or that IFNa elicits its effects through STAT1-inde-
pendent pathways (Lu et al., 2010). Normal HSC function is regu-
lated by basal IFN tone (Baldridge et al., 2010; Essers et al.,
2009; Zhao et al., 2010) and increased IFNg or IFNa signaling
results in HSC exhaustion (Trumpp et al., 2010). Hence, within
a JAK2V617F-positive population, a subclone that acquires
adefect inSTAT1activationmaynotonlygive rise toerythrocytosis
but also display a competitive advantagewithin theHSC compart-
ment, thus providing a potential mechanism for clonal evolution.EXPERIMENTAL PROCEDURES
Patients and Samples
A total of 36 MPN cases (18 men/18 women) with a median age of 64 (ranging
from 12 to 89 years), diagnosed with either essential thrombocythemia or poly-
cythemia vera according to the World Health Organization (WHO) criteria were
recruited for this study from the MPN clinic at the Addenbrooke’s Hospital in
Cambridge, UK. All patients were shown to possess the JAK2V617Fmutation
in granulocyte DNA using allele-specific PCR. Two PV patients and one ET
patient also possessed mutations in TET2. None harbored MPL or JAK2
exon 12 mutations. The clinical and biological features of all patients at diag-
nosis are listed in Table S1. All patients gave informed written consent before
participating in the study. The study was approved by the Cambridge and
Eastern Region Ethics Committee, and was carried out in accordance with
the principles of the Declaration of Helsinki. Venous blood samples (20 ml)
were collected from each patient, and peripheral blood mononuclear cells
were isolated using Lymphoprep (Axis Shield PLC) according to the manufac-Canturer’s protocols, and plated in Methocult (H4531; Stem Cell Technologies)
supplemented with 0.01 U/ml erythropoietin at a density of 3 3 105 cells/ml.
Cultures were incubated at 37C for 14 days.
RNA Extraction
For each patient, individual BFU-E colonies were plucked into 100 ml of Buffer
RLT (QIAGEN). A portion of the sample in Buffer RLT for each colony was used
for genomic DNA (gDNA) extraction, followed by genotyping by real-time
qPCR to determine its JAK2mutational status, as described previously (Levine
et al., 2006). Colonies with V617F percentages below 10% were designated
‘‘wild-type’’ and those between 40% and 60% were designated ‘‘heterozy-
gous.’’ Colonies not fulfilling any of the two criteria were discarded. Up to
20 colonies of each JAK2 genotype were pooled, and total cellular RNA
from each sample was isolated using the QIAGEN RNeasy kit following the
manufacturer’s protocols. RNA quality was assessed by nano electrophoresis
using the Pico lab-on-a-chip assay (Bioanalyzer, Agilent Technologies) and by
agarose gel electrophoresis.
Microarray Analysis
Total RNA (100 ng) obtained from wild-type and V617F-heterozygous BFU-E
colonies from each patient were reverse transcribed into cDNA and amplified
by in vitro transcription into biotinylated cRNA using the Illumina TotalPrep
RNA Amplification Kit (Ambion). For each sample, 1.5 mg of amplified cRNA
was used for hybridization onto Illumina Human-6 v2.0 Expression BeadChips,
comprising 48,000 oligonucleotide probes.
Single Cell Erythroid/Megakaryocyte Differentiation Cultures
Peripheral blood mononuclear cells were obtained from peripheral blood of
patients diagnosed with ET over a Ficoll gradient, and CD34+ cells were
then selected using a magnetic cell sorting system (Miltenyi Biotech), accord-
ing to manufacturer’s instructions. Purified CD34+ cells were immediately in-
fected with either an empty vector or a dominant negative STAT1-expressing
lentiviruses by spinoculation for 2 hr in the presence of 4 mg/ml polybrene,
followed by culturing for 2 days in SFEM medium supplemented with
100 ng/ml Flt3 ligand and 10 ng/ml rhTPO. Subsequently, cells were sorted
based on GFP positivity and seeded as single cells in a well of a 96-well plate
with SFEM media supplemented with 25 ng/ml rhSCF, 0.5 U/ml rhEPO,
100 ng/ml rhTPO, 30 mg/ml holo-transferrin, 10 nM b-mercaptoethanol, and
4 mg/ml dexamethasone to support both erythroid and megakaryocytic differ-
entiation. After 7 additional days in culture, 10% of the cells were removed for
JAK2 genotyping as described above. After an additional 7–14 days of culture,
V617F-heterozygous clones were analyzed for GPA and CD41 expression.
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